Drug discovery of therapies for duchenne muscular dystrophy

Journal of Biomolecular Screening

Volumn 20, Issue 10, 2015, Pages 1189-1203

  Blat, Yuval ^a   Blat, Shachar ^b  

^a University of Pittsburgh ^*  (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Duchenne muscular dystrophy; dystrophin; review; skeletal muscle

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATALUREN; CAT 1004; CREATINE KINASE; DERISAPERSEN; DYSTROPHIN; ETEPLIRSEN; GIVINOSTAT; HALOFUGINONE; HT 100; IDEBENONE; IMATINIB; MUSCLE ENZYME; NAPROXCINOD; PHOSPHODIESTERASE V INHIBITOR; PROTEIN; PROTEINASE; SILDENAFIL; SMTC 1100; TADALAFIL; UNCLASSIFIED DRUG; UTROPHIN; VBP 15; BENZOXAZOLE DERIVATIVE; CALCIUM; EZUTROMID; OXADIAZOLE DERIVATIVE;

CALCIUM HOMEOSTASIS; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVATION; EX VIVO STUDY; FIBROSIS; HEALTH CARE QUALITY; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MUSCLE CELL; MYOBLAST; MYOTUBE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE;

ANIMALS; ANTIOXIDANTS; BENZOXAZOLES; CALCIUM; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DYSTROPHIN; GENE EXPRESSION; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OXADIAZOLES;

EID: 84948391121     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115586535     Document Type: Review

References (139)

1. Blake D. J., Weir A., Newey S. E., et al. Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle. Physiol. Rev. 2002, 82, 291-329.
2. Bushby K., Finkel R., Birnkrant D. J., et al. Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Pharmacological and Psychosocial Management. Lancet Neurol. 2010, 9, 77-93.
3. Nigro V., Piluso G., Spectrum of Muscular Dystrophies Associated with Sarcolemmal-Protein Genetic Defects. Biochim. Biophys. Acta. 2015, 1852, 585-593.
4. Mendell J. R., Shilling C., Leslie N. D., et al. Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy. Ann. Neurol. 2012, 71, 304-313.
5. Verhaart I. E., Aartsma-Rus A., Gene Therapy for Duchenne Muscular Dystrophy. Curr. Opin. Neurol. 2012, 25, 588-596.
6. Spurney C. F., Cardiomyopathy of Duchenne Muscular Dystrophy: Current Understanding and Future Directions. Muscle Nerve. 2011, 44, 8-19.
7. Hall A. K., Carlson M. R., The Current Status of Orphan Drug Development in Europe and the US. Intractable Rare Dis. Res. 2014, 3, 1-7.
8. Hoffman E. P., Brown R. H. Jr., Kunkel L. M., Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy Locus. Cell. 1987, 51, 919-928.
9. Wallace G. Q., McNally E. M., Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies. Annu. Rev. Physiol. 2009, 71, 37-57.
10. Flanigan K. M., Dunn D. M., von Niederhausern A., et al. Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort. Hum. Mutat. 2009, 30, 1657-1666.
11. England S. B., Nicholson L. V., Johnson M. A., et al. Very Mild Muscular Dystrophy Associated with the Deletion of 46% of Dystrophin. Nature. 1990, 343, 180-182.
12. Ibraghimov-Beskrovnaya O., Ervasti J. M., Leveille C. J., et al. Primary Structure of Dystrophin-Associated Glycoproteins Linking Dystrophin to the Extracellular Matrix. Nature. 1992, 355, 696-702.
13. Shin J., Tajrishi M. M., Ogura Y., et al. Wasting Mechanisms in Muscular Dystrophy. Int. J. Biochem. Cell Biol. 2013, 45, 2266-2279.
14. Culligan K. G., Ohlendieck K., Abnormal Calcium Handling in Muscular Dystrophy. Appl. Myology. 2002, 12, 147-157.
15. Altamirano F., Lopez J. R., Henriquez C., et al. Increased Resting Intracellular Calcium Modulates NF-Kappa-B-Dependent Inducible Nitric-Oxide Synthase Gene Expression in Dystrophic mdx Skeletal Myotubes. J. Biol. Chem. 2012, 287, 20876-20887.
16. Fraysse B., Liantonio A., Cetrone M., et al. The Alteration of Calcium Homeostasis in Adult Dystrophic mdx Muscle Fibers Is Worsened by a Chronic Exercise In Vivo. Neurobiol. Dis. 2004, 17, 144-154.
17. Mallouk N., Jacquemond V., Allard B., Elevated Subsarcolemmal Ca2+ in mdx Mouse Skeletal Muscle Fibers Detected with Ca2+-Activated K+ Channels. Proc. Natl. Acad. Sci. USA. 2000, 97, 4950-4955.
18. Bellinger A. M., Reiken S., Carlson C., et al. Hypernitrosylated Ryanodine Receptor Calcium Release Channels Are Leaky in Dystrophic Muscle. Nat. Med. 2009, 15, 325-330.
19. Fauconnier J., Thireau J., Reiken S., et al. Leaky RyR2 Trigger Ventricular Arrhythmias in Duchenne Muscular Dystrophy. Proc. Natl. Acad. Sci. USA. 2010, 107, 1559-1564.
20. Goll D. E., Thompson V. F., Li H., et al. The Calpain System. Physiol. Rev. 2003, 83, 731-801.
21. Lilienbaum A., Israel A., From Calcium to NF-Kappa B Signaling Pathways in Neurons. Mol. Cell Biol. 2003, 23, 2680-2698.
22. Haycock J. W., MacNeil S., Jones P., et al. Oxidative Damage to Muscle Protein in Duchenne Muscular Dystrophy. Neuroreport. 1996, 8, 357-361.
23. Kar N. C., Pearson C. M., Catalase, Superoxide Dismutase, Glutathione Reductase and Thiobarbituric Acid-Reactive Products in Normal and Dystrophic Human Muscle. Clin. Chim. Acta. 1979, 94, 277-280.
24. Spurney C. F., Knoblach S., Pistilli E. E., et al. Dystrophin-Deficient Cardiomyopathy in Mouse: Expression of Nox4 and Lox Are Associated with Fibrosis and Altered Functional Parameters in the Heart. Neuromuscul. Disord. 2008, 18, 371-381.
25. Whitehead N. P., Yeung E. W., Froehner S. C., et al. Skeletal Muscle NADPH Oxidase Is Increased and Triggers Stretch-Induced Damage in the mdx Mouse. PLoS ONE. 2010, 5, e15354.
26. Tidball J. G., Inflammatory Processes in Muscle Injury and Repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288, R345-R353.
27. Cohn R. D., van Erp C., Habashi J. P., et al. Angiotensin II Type 1 Receptor Blockade Attenuates TGF-Beta-Induced Failure of Muscle Regeneration in Multiple Myopathic States. Nat. Med. 2007, 13, 204-210.
28. Li Y., Foster W., Deasy B. M., et al. Transforming Growth Factor-Beta1 Induces the Differentiation of Myogenic Cells into Fibrotic Cells in Injured Skeletal Muscle: A Key Event in Muscle Fibrogenesis. Am. J. Pathol. 2004, 164, 1007-1019.
29. Hollinger K., Selsby J. T., The Physiological Response of Protease Inhibition in Dystrophic Muscle. Acta Physiol. (Oxf). 2013, 208, 234-244.
30. Bulfield G., Siller W. G., Wight P. A., et al. X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse. Proc. Natl. Acad. Sci. USA. 1984, 81, 1189-1192.
31. Grounds M. D., Radley H. G., Lynch G. S., et al. Towards Developing Standard Operating Procedures for Pre-Clinical Testing in the mdx Mouse Model of Duchenne Muscular Dystrophy. Neurobiol. Dis. 2008, 31, 1-19.
32. Spurney C. F., Gordish-Dressman H., Guerron A. D., et al. Preclinical Drug Trials in the mdx Mouse: Assessment of Reliable and Sensitive Outcome Measures. Muscle Nerve. 2009, 39, 591-602.
33. Chamberlain J. S., Metzger J., Reyes M., et al. Dystrophin-Deficient mdx Mice Display a Reduced Life Span and Are Susceptible to Spontaneous Rhabdomyosarcoma. FASEB J. 2007, 21, 2195-2204.
34. Deconinck A. E., Rafael J. A., Skinner J. A., et al. Utrophin-Dystrophin-Deficient Mice as a Model for Duchenne Muscular Dystrophy. Cell. 1997, 90, 717-727.
35. Grady R. M., Teng H., Nichol M. C., et al. Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy. Cell. 1997, 90, 729-738.
36. Fukada S., Morikawa D., Yamamoto Y., et al. Genetic Background Affects Properties of Satellite Cells and mdx Phenotypes. Am. J. Pathol. 2010, 176, 2414-2424.
37. Sacco A., Mourkioti F., Tran R., et al. Short Telomeres and Stem Cell Exhaustion Model Duchenne Muscular Dystrophy in mdx/mTR Mice. Cell. 2010, 143, 1059-1071.
38. Brussee V., Tardif F., Tremblay J. P., Muscle Fibers of mdx Mice Are More Vulnerable to Exercise Than Those of Normal Mice. Neuromuscul. Disord. 1997, 7, 487-492.
39. De Luca A., Pierno S., Liantonio A., et al. Enhanced Dystrophic Progression in mdx Mice by Exercise and Beneficial Effects of Taurine and Insulin-Like Growth Factor-1. J. Pharmacol. Exp. Ther. 2003, 304, 453-463.
40. Araki E., Nakamura K., Nakao K., et al. Targeted Disruption of Exon 52 in the Mouse Dystrophin Gene Induced Muscle Degeneration Similar to That Observed in Duchenne Muscular Dystrophy. Biochem. Biophys. Res. Commun. 1997, 238, 492-497.
41. Collins C. A., Morgan J. E., Duchenne's Muscular Dystrophy: Animal Models Used to Investigate Pathogenesis and Develop Therapeutic Strategies. Int. J. Exp. Pathol. 2003, 84, 165-172.
42. Nakamura A., Takeda S., Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications. J. Biomed. Biotechnol. 2011, 2011, 184393.
43. Barthelemy I., Pinto-Mariz F., Yada E., et al. Predictive Markers of Clinical Outcome in the GRMD Dog Model of Duchenne Muscular Dystrophy. Dis. Model. Mech. 2014, 7, 1253-1261.
44. Kawahara G., Karpf J. A., Myers J. A., et al. Drug Screening in a Zebrafish Model of Duchenne Muscular Dystrophy. Proc. Natl. Acad. Sci. USA. 2011, 108, 5331-5336.
45. Tanabe Y., Esaki K., Nomura T., Skeletal Muscle Pathology in X Chromosome-Linked Muscular Dystrophy (mdx) Mouse. Acta Neuropathol. 1986, 69, 91-95.
46. Torres L. F., Duchen L. W., The Mutant mdx: Inherited Myopathy in the Mouse. Morphological Studies of Nerves, Muscles and End-Plates. Brain. 1987, 110, 269-299.
47. Greally E., Davison B. J., Blain A., et al. Heterogeneous Abnormalities of In-Vivo Left Ventricular Calcium Influx and Function in Mouse Models of Muscular Dystrophy Cardiomyopathy. J. Cardiovasc. Magn. Reson. 2013, 15, 4.
48. Spurney C. F., Cha H. J., Sali A., et al. Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin Beta-4 in the Dystrophin Deficient Mouse. PLoS ONE. 2010, 5, e8976.
49. Gregorevic P., Plant D. R., Lynch G. S., Administration of Insulin-Like Growth Factor-I Improves Fatigue Resistance of Skeletal Muscles from Dystrophic mdx Mice. Muscle Nerve. 2004, 30, 295-304.
50. Zanou N., Iwata Y., Schakman O., et al. Essential Role of TRPV2 Ion Channel in the Sensitivity of Dystrophic Muscle to Eccentric Contractions. FEBS Lett. 2009, 583, 3600-3604.
51. Sekiguchi M., Zushida K., Yoshida M., et al. A Deficit of Brain Dystrophin Impairs Specific Amygdala GABAergic Transmission and Enhances Defensive Behaviour in Mice. Brain. 2009, 132, 124-135.
52. Dupont-Versteegden E. E., McCarter R. J., Katz M. S., Voluntary Exercise Decreases Progression of Muscular Dystrophy in Diaphragm of mdx Mice. J. Appl. Physiol. (1985). 1994, 77, 1736-1741.
53. Crisp A., Yin H., Goyenvalle A., et al. Diaphragm Rescue Alone Prevents Heart Dysfunction in Dystrophic Mice. Hum. Mol. Genet. 2011, 20, 413-421.
54. Stuckey D. J., Carr C. A., Camelliti P., et al. In Vivo MRI Characterization of Progressive Cardiac Dysfunction in the mdx Mouse Model of Muscular Dystrophy. PLoS ONE. 2012, 7, e28569.
55. Moise N. S., Valentine B. A., Brown C. A., et al. Duchenne's Cardiomyopathy in a Canine Model: Electrocardiographic and Echocardiographic Studies. J. Am. Coll. Cardiol. 1991, 17, 812-820.
56. Huang P., Cheng G., Lu H., et al. Impaired Respiratory Function in mdx and mdx/utrn(+/â') Mice. Muscle Nerve. 2011, 43, 263-267.
57. Gayraud J., Matecki S., Hnia K., et al. Ventilation during Air Breathing and in Response to Hypercapnia in 5 and 16 Month-Old mdx and C57 Mice. J. Muscle Res. Cell Motil. 2007, 28, 29-37.
58. Haws C. M., Lansman J. B., Developmental Regulation of Mechanosensitive Calcium Channels in Skeletal Muscle from Normal and mdx Mice. Proc. Biol. Sci. 1991, 245, 173-177.
59. Lovering R. M., Michaelson L., Ward C. W., Malformed mdx Myofibers Have Normal Cytoskeletal Architecture yet Altered EC Coupling and Stress-Induced Ca2+ Signaling. Am. J. Physiol. Cell Physiol. 2009, 297, C571-C580.
60. Robin G., Berthier C., Allard B., Sarcoplasmic Reticulum Ca2+ Permeation Explored from the Lumen Side in mdx Muscle Fibers under Voltage Control. J. Gen. Physiol. 2012, 139, 209-218.
61. Teichmann M. D., Wegner F. V., Fink R. H., et al. Inhibitory Control over Ca(2+) Sparks via Mechanosensitive Channels Is Disrupted in Dystrophin Deficient Muscle but Restored by Mini-Dystrophin Expression. PLoS ONE. 2008, 3, e3644.
62. Ather S., Wang W., Wang Q., et al. Inhibition of CaMKII Phosphorylation of RyR2 Prevents Inducible Ventricular Arrhythmias in Mice with Duchenne Muscular Dystrophy. Heart Rhythm. 2013, 10, 592-599.
63. Gonzalez D. R., Treuer A. V., Lamirault G., et al. NADPH Oxidase-2 Inhibition Restores Contractility and Intracellular Calcium Handling and Reduces Arrhythmogenicity in Dystrophic Cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H710-H721.
64. Kyrychenko S., Polakova E., Kang C., et al. Hierarchical Accumulation of RyR Post-Translational Modifications Drives Disease Progression in Dystrophic Cardiomyopathy. Cardiovasc. Res. 2013, 97, 666-675.
65. Rando T. A., Blau H. M., Primary Mouse Myoblast Purification, Characterization, and Transplantation for Cell-Mediated Gene Therapy. J. Cell Biol. 1994, 125, 1275-1287.
66. Fong P. Y., Turner P. R., Denetclaw W. F., et al. Increased Activity of Calcium Leak Channels in Myotubes of Duchenne Human and mdx Mouse Origin. Science. 1990, 250, 673-676.
67. Morgan J. E., Beauchamp J. R., Pagel C. N., et al. Myogenic Cell Lines Derived from Transgenic Mice Carrying a Thermolabile T Antigen: A Model System for the Derivation of Tissue-Specific and Mutation-Specific Cell Lines. Dev. Biol. 1994, 162, 486-498.
68. O'Leary D. A., Sharif O., Anderson P., et al. Identification of Small Molecule and Genetic Modulators of AON-Induced Dystrophin Exon Skipping by High-Throughput Screening. PLoS ONE. 2009, 4, e8348.
69. Blau H. M., Chiu C. P., Webster C., Cytoplasmic Activation of Human Nuclear Genes in Stable Heterocaryons. Cell. 1983, 32, 1171-1180.
70. Hu Y., Wu B., Zillmer A., et al. Guanine Analogues Enhance Antisense Oligonucleotide-Induced Exon Skipping in Dystrophin Gene In Vitro and In Vivo. Mol. Ther. 2010, 18, 812-818.
71. Kendall G. C., Mokhonova E. I., Moran M., et al. Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy. Sci. Transl. Med. 2012, 4, 164ra160.
72. Moorwood C., Lozynska O., Suri N., et al. Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening. PLoS ONE. 2011, 6, e26169.
73. Salani S., Donadoni C., Rizzo F., et al. Generation of Skeletal Muscle Cells from Embryonic and Induced Pluripotent Stem Cells as an In Vitro Model and for Therapy of Muscular Dystrophies. J. Cell Mol. Med. 2012, 16, 1353-1364.
74. Abujarour R., Bennett M., Valamehr B., et al. Myogenic Differentiation of Muscular Dystrophy-Specific Induced Pluripotent Stem Cells for Use in Drug Discovery. Stem Cells Transl. Med. 2014, 3, 149-160.
75. Lin B., Li Y., Han L., et al. Modeling and Studying Mechanism of Dilated Cardiomyopathy Using Induced Pluripotent Stem Cells Derived from Duchenne Muscular Dystrophy (DMD) Patients. Dis. Model. Mech. 2015.
76. Guan X., Mack D. L., Moreno C. M., et al. Dystrophin-Deficient Cardiomyocytes Derived from Human Urine: New Biologic Reagents for Drug Discovery. Stem Cell Res. 2014, 12, 467-480.
77. Li H. L., Fujimoto N., Sasakawa N., et al. Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015, 4, 143-154.
78. Govoni A., Magri F., Brajkovic S., et al. Ongoing Therapeutic Trials and Outcome Measures for Duchenne Muscular Dystrophy. Cell Mol. Life Sci. 2013, 70, 4585-4602.
79. Cacchiarelli D., Legnini I., Martone J., et al. miRNAs as Serum Biomarkers for Duchenne Muscular Dystrophy. EMBO Mol. Med. 2011, 3, 258-265.
80. Zaharieva I. T., Calissano M., Scoto M., et al. Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy. PLoS ONE. 2013, 8, e80263.
81. McDonald C. M., Henricson E. K., Abresch R. T., et al. The 6-Minute Walk Test and Other Endpoints in Duchenne Muscular Dystrophy: Longitudinal Natural History Observations over 48 Weeks from a Multicenter Study. Muscle Nerve. 2013, 48, 343-356.
82. Henricson E. K., Abresch R. T., Cnaan A., et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: Glucocorticoid Treatment Preserves Clinically Meaningful Functional Milestones and Reduces Rate of Disease Progression as Measured by Manual Muscle Testing and Other Commonly Used Clinical Trial Outcome Measures. Muscle Nerve. 2013, 48, 55-67.
83. Buyse G. M., Goemans N., van den Hauwe M., et al. Effects of Glucocorticoids and Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy. Pediatr. Pulmonol. 2013, 48, 912-920.
84. Network T.-N. N., Standards of Care for Duchenne Muscular Dystrophy Brief TREAT-NMD Recommendations. http://www.parentprojectmd.org/site/DocServer/TREAT-NMD-DMD-interim-recommendations.pdf.
85. Judge D. P., Kass D. A., Thompson W. R., et al. Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. Am. J. Cardiovasc. Drugs. 2011, 11, 287-294.
86. Bushby K., Finkel R., Wong B., et al. Ataluren Treatment of Patients with Nonsense Mutation Dystrophinopathy. Muscle Nerve. 2014, 50, 477-487.
87. Welch E. M., Barton E. R., Zhuo J., et al. PTC124 Targets Genetic Disorders Caused by Nonsense Mutations. Nature. 2007, 447, 87-91.
88. Ryan N. J., Ataluren: First Global Approval. Drugs. 2014, 74, 1709-1714.
89. Kayali R., Ku J. M., Khitrov G., et al. Read-Through Compound 13 Restores Dystrophin Expression and Improves Muscle Function in the mdx Mouse Model for Duchenne Muscular Dystrophy. Hum. Mol. Genet. 2012, 21, 4007-4020.
90. McElroy S. P., Nomura T., Torrie L. S., et al. A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays. PLoS Biol. 2013, 11, e1001593.
91. Hoffman E. P., Bronson A., Levin A. A., et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle Progress in Exon Skipping and Stop Codon Read Through. Am. J. Pathol. 2011, 179, 12-22.
92. Malerba A., Sharp P. S., Graham I. R., et al. Chronic Systemic Therapy with Low-Dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx Mice. Mol. Ther. 2011, 19, 345-354.
93. Wu B., Xiao B., Cloer C., et al. One-Year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic mdx Mice. Mol. Ther. 2011, 19, 576-583.
94. Mercuri E., Muntoni F., Muscular Dystrophy: New Challenges and Review of the Current Clinical Trials. Curr. Opin. Pediatr. 2013, 25, 701-707.
95. Goemans N. M., Tulinius M., van den Akker J. T., et al. Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy. N. Engl. J. Med. 2011, 364, 1513-1522.
96. Voit T., Topaloglu H., Straub V., et al. Safety and Efficacy of Drisapersen for the Treatment of Duchenne Muscular Dystrophy (DEMAND II): An Exploratory, Randomised, Placebo-Controlled Phase 2 Study. Lancet Neurol. 2014, 13, 987-996.
97. Mendell J. R., Rodino-Klapac L. R., Sahenk Z., et al. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy. Ann. Neurol. 2013, 74, 637-647.
98. Yokota T., Pistilli E., Duddy W., et al. Potential of Oligonucleotide-Mediated Exon-Skipping Therapy for Duchenne Muscular Dystrophy. Expert Opin. Biol. Ther. 2007, 7, 831-842.
99. Bostick B., Shin J. H., Yue Y., et al. AAV Micro-Dystrophin Gene Therapy Alleviates Stress-Induced Cardiac Death but Not Myocardial Fibrosis in >21-M-Old mdx Mice, an End-Stage Model of Duchenne Muscular Dystrophy Cardiomyopathy. J. Mol. Cell Cardiol. 2012, 53, 217-222.
100. Gregorevic P., Blankinship M. J., Allen J. M., et al. Systemic Microdystrophin Gene Delivery Improves Skeletal Muscle Structure and Function in Old Dystrophic mdx Mice. Mol. Ther. 2008, 16, 657-664.
101. Barbash I. M., Cecchini S., Faranesh A. Z., et al. MRI Roadmap-Guided Transendocardial Delivery of Exon-Skipping Recombinant Adeno-Associated Virus Restores Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy. Gene Ther. 2013, 20, 274-282.
102. Bowles D. E., McPhee S. W., Li C., et al. Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector. Mol. Ther. 2012, 20 (2), 443-455.
103. Mendell J. R., Campbell K., Rodino-Klapac L., et al. Dystrophin Immunity in Duchenne's Muscular Dystrophy. N. Engl. J. Med. 2010, 363, 1429-1437.
104. Tinsley J., Deconinck N., Fisher R., et al. Expression of Full-Length Utrophin Prevents Muscular Dystrophy in mdx Mice. Nat. Med. 1998, 4, 1441-1444.
105. Tinsley J. M., Potter A. C., Phelps S. R., et al. Amelioration of the Dystrophic Phenotype of mdx Mice Using a Truncated Utrophin Transgene. Nature. 1996, 384, 349-353.
106. Tinsley J. M., Fairclough R. J., Storer R., et al. Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse. PLoS ONE. 2011, 6, e19189.
107. Goonasekera S. A., Lam C. K., Millay D. P., et al. Mitigation of Muscular Dystrophy in Mice by SERCA Overexpression in Skeletal Muscle. J. Clin. Invest. 2011, 121, 1044-1052.
108. Altamirano F., Valladares D., Henriquez-Olguin C., et al. Nifedipine Treatment Reduces Resting Calcium Concentration, Oxidative and Apoptotic Gene Expression, and Improves Muscle Function in Dystrophic mdx Mice. PLoS ONE. 2013, 8, e81222.
109. Capogrosso R. F., Cozzoli A., Giustino A., et al. Effects of S48168/Arm210, a New Rycal Compound, on Pathology Related Signs of Exercised Dystrophic mdx Mouse.; in 19th WMS Congress; Elsevier: Berlin; 2014.
110. Terrill J. R., Radley-Crabb H. G., Grounds M. D., et al. N-Acetylcysteine Treatment of Dystrophic mdx Mice Results in Protein Thiol Modifications and Inhibition of Exercise Induced Myofibre Necrosis. Neuromuscul. Disord. 2012, 22, 427-434.
111. Spurney C. F., Rocha C. T., Henricson E., et al. CINRG Pilot Trial of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy. Muscle Nerve. 2011, 44, 174-178.
112. Buyse G. M., Van der Mieren G., Erb M., et al. Long-Term Blinded Placebo-Controlled Study of SNT-MC17/Idebenone in the Dystrophin Deficient Mdx Mouse: Cardiac Protection and Improved Exercise Performance. Eur. Heart J. 2009, 30, 116-124.
113. Buyse G. M., Goemans N., van den Hauwe M., et al. Idebenone as a Novel, Therapeutic Approach for Duchenne Muscular Dystrophy: Results from a 12 Month, Double-Blind, Randomized Placebo-Controlled Trial. Neuromuscul. Disord. 2011, 21, 396-405.
114. How to Tackle Respiratory Failure in DMD Pharmacotherapy beyond Steroids. http://www.santhera.com/downloads/Orphan-Drug-Summit-2014.pdf.
115. Heier C. R., Damsker J. M., Yu Q., et al. VBP15, a Novel Anti-Inflammatory and Membrane-Stabilizer, Improves Muscular Dystrophy without Side Effects. EMBO Mol. Med. 2013, 5, 1569-1585.
116. Fiorucci S., Distrutti E., COXIBs, CINODs and H(2)S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs. Curr. Med. Chem. 2011, 18, 3494-3505.
117. Uaesoontrachoon K., Quinn J. L., Tatem K. S., et al. Long-Term Treatment with Naproxcinod Significantly Improves Skeletal and Cardiac Disease Phenotype in the mdx Mouse Model of Dystrophy. Hum. Mol. Genet. 2014, 23, 3239-3249.
118. Sciorati C., Miglietta D., Buono R., et al. A Dual Acting Compound Releasing Nitric Oxide (NO) and Ibuprofen, NCX 320, Shows Significant Therapeutic Effects in a Mouse Model of Muscular Dystrophy. Pharmacol. Res. 2011, 64, 210-217.
119. Nelson C. A., Hunter R. B., Quigley L. A., et al. Inhibiting TGF-Beta Activity Improves Respiratory Function in mdx Mice. Am. J. Pathol. 2011, 178, 2611-2621.
120. Cozzoli A., Nico B., Sblendorio V. T., et al. Enalapril Treatment Discloses an Early Role of Angiotensin II in Inflammation- and Oxidative Stress-Related Muscle Damage in Dystrophic mdx Mice. Pharmacol. Res. 2011, 64, 482-492.
121. Morales M. G., Cabrera D., Cespedes C., et al. Inhibition of the Angiotensin-Converting Enzyme Decreases Skeletal Muscle Fibrosis in Dystrophic Mice by a Diminution in the Expression and Activity of Connective Tissue Growth Factor (CTGF/CCN-2). Cell Tissue Res. 2013, 353, 173-187.
122. Duboc D., Meune C., Lerebours G., et al. Effect of Perindopril on the Onset and Progression of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy. J. Am. Coll. Cardiol. 2005, 45, 855-857.
123. Duboc D., Meune C., Pierre B., et al. Perindopril Preventive Treatment on Mortality in Duchenne Muscular Dystrophy: 10 Years' Follow-Up. Am. Heart J. 2007, 154, 596-602.
124. Ramaciotti C., Heistein L. C., Coursey M., et al. Left Ventricular Function and Response to Enalapril in Patients with Duchenne Muscular Dystrophy during the Second Decade of Life. Am. J. Cardiol. 2006, 98, 825-827.
125. Bizario J. C., Cerri D. G., Rodrigues L. C., et al. Imatinib Mesylate Ameliorates the Dystrophic Phenotype in Exercised mdx Mice. J. Neuroimmunol. 2009, 212, 93-101.
126. Huang P., Zhao X. S., Fields M., et al. Imatinib Attenuates Skeletal Muscle Dystrophy in mdx Mice. FASEB J. 2009, 23, 2539-2548.
127. McGaha T. L., Phelps R. G., Spiera H., et al. Halofuginone, an Inhibitor of Type-I Collagen Synthesis and Skin Sclerosis, Blocks Transforming-Growth-Factor-Beta-Mediated Smad3 Activation in Fibroblasts. J. Invest. Dermatol. 2002, 118, 461-470.
128. Huebner K. D., Jassal D. S., Halevy O., et al. Functional Resolution of Fibrosis in mdx Mouse Dystrophic Heart and Skeletal Muscle by Halofuginone. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H1550-H1561.
129. Turgeman T., Hagai Y., Huebner K., et al. Prevention of Muscle Fibrosis and Improvement in Muscle Performance in the mdx Mouse by Halofuginone. Neuromuscul. Disord. 2008, 18, 857-868.
130. Chao D. S., Silvagno F., Bredt D. S., Muscular Dystrophy in mdx Mice Despite Lack of Neuronal Nitric Oxide Synthase. J. Neurochem. 1998, 71, 784-789.
131. Sander M., Chavoshan B., Harris S. A., et al. Functional Muscle Ischemia in Neuronal Nitric Oxide Synthase-Deficient Skeletal Muscle of Children with Duchenne Muscular Dystrophy. Proc. Natl. Acad. Sci. USA. 2000, 97, 13818-13823.
132. Burdi R., Rolland J. F., Fraysse B., et al. Multiple Pathological Events in Exercised Dystrophic mdx Mice Are Targeted by Pentoxifylline: Outcome of a Large Array of In Vivo and Ex Vivo Tests. J. Appl. Physiol. (1985). 2009, 106, 1311-1324.
133. Percival J. M., Whitehead N. P., Adams M. E., et al. Sildenafil Reduces Respiratory Muscle Weakness and Fibrosis in the mdx Mouse Model of Duchenne Muscular Dystrophy. J. Pathol. 2012, 228, 77-87.
134. Asai A., Sahani N., Kaneki M., et al. Primary Role of Functional Ischemia, Quantitative Evidence for the Two-Hit Mechanism, and Phosphodiesterase-5 Inhibitor Therapy in Mouse Muscular Dystrophy. PLoS ONE. 2007, 2, e806.
135. Nelson M. D., Rader F., Tang X., et al. PDE5 Inhibition Alleviates Functional Muscle Ischemia in Boys with Duchenne Muscular Dystrophy. Neurology. 2014, 82, 2085-2091.
136. Leung D. G., Herzka D. A., Thompson W. R., et al. Sildenafil Does Not Improve Cardiomyopathy in Duchenne/Becker Muscular Dystrophy. Ann. Neurol. 2014, 76, 541-549.
137. Bogdanovich S., Krag T. O., Barton E. R., et al. Functional Improvement of Dystrophic Muscle by Myostatin Blockade. Nature. 2002, 420, 418-421.
138. Mozzetta C., Consalvi S., Saccone V., et al. Fibroadipogenic Progenitors Mediate the Ability of HDAC Inhibitors to Promote Regeneration in Dystrophic Muscles of Young, but Not Old Mdx Mice. EMBO Mol. Med. 2013, 5, 626-639.
139. Consalvi S., Mozzetta C., Bettica P., et al. Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat. Mol. Med. 2013, 19, 79-87.